LOGC vs OZON

ContextLogic Inc.

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Ozon Holdings PLC

Ozon Holdings PLC, together with its subsidiaries, operates as an internet retailer of multi-category consumer products to the general public primarily in the Russian Federation. The company offers products in various categories that include electronics, home and décor products, children's goods, fast moving consumer goods, fresh food, and car parts. It also manages an online marketplace platform that enables third-party sellers to offer their products to consumers on its mobile apps, as well as ozon.ru and ozon.travel websites. In addition, the company provides advertising services to vendors and third-party sellers; and airline and railway tickets. Ozon Holdings PLC was incorporated in 1999 and is based in Nicosia, Cyprus.